Nanobiotix S.A. Sponsored ADR (NASDAQ:NBTX - Get Free Report) shares reached a new 52-week high on Tuesday . The company traded as high as $18.49 and last traded at $18.02, with a volume of 167265 shares traded. The stock had previously closed at $16.24.
Analyst Upgrades and Downgrades
A number of research firms recently weighed in on NBTX. Leerink Partners set a $14.00 price target on Nanobiotix in a report on Thursday, September 18th. HC Wainwright restated a "buy" rating on shares of Nanobiotix in a report on Friday, September 19th. Two equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $11.00.
Check Out Our Latest Stock Report on NBTX
Nanobiotix Price Performance
The stock has a fifty day moving average price of $9.20 and a two-hundred day moving average price of $5.84.
Hedge Funds Weigh In On Nanobiotix
An institutional investor recently bought a new position in Nanobiotix stock. Millennium Management LLC purchased a new position in Nanobiotix S.A. Sponsored ADR (NASDAQ:NBTX - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 13,452 shares of the company's stock, valued at approximately $39,000. 38.81% of the stock is currently owned by institutional investors and hedge funds.
Nanobiotix Company Profile
(
Get Free Report)
Nanobiotix SA, a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Nanobiotix, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Nanobiotix wasn't on the list.
While Nanobiotix currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
